Clinical trial registry record

Role of HIF-1α in Skeletal Muscle Aging

A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 14, 2017.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03371134
Last registry update
December 14, 2017
Status
Unknown
Phase
Phase not reported
Sponsor
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Enrollment
16
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
OBSERVATIONAL
Evidence population
Human clinical study registration
Participants
16
Population
ALL · 18 Years to 90 Years
Duration
2018-01-10 to 2020-07-26
Intervention
Harvesting of muscular biopsies
Comparator
Not reported
Outcomes measured
Evaluation of HIF-1a expression levels in satellite cells isolated from sarcopenic and young — 1 year; Evaluation of sarcopenic profile in satellite cells harvested from old sarcopenic patients — 6 months; Correlation of HIF-1a levels with the degree of sarcopenia in the satellite cells of old sarcopenic patients — 1 year; Evaluation of differences in satellite cells number between young and old patients — 6 months; Evaluation of HIF-1a stabilization on satellite cells treated with PHDs inhibitors — 1 year; Evaluation of satellite cell proliferation in cells treated with PHDs inhibitors — 1 year; Evaluation of satellite cell differentiation in cells treated with PHDs inhibitors — 1 year
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Sarcopenia · 100%Title contains controlled term: muscle aging. Abstract contains controlled term: sarcopenia. Source terminology contains: sarcopenia. Title supplies longevity context: aging. Study type is explicitly identified as OBSERVATIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

sarcopenia
Open primary sourceExport JSON